By Stephen Nakrosis
Mirati Therapeutics said on Friday the U.K.’s Medicines and Healthcare Products Regulatory Agency gave conditional marketing approval for Krazati to treat certain non-small cell lung cancer patients.
Krazati was given approval as a treatment for adult patients who have “advanced non-small cell lung cancer with KRAS(G12C) mutation and have progressive disease after prior therapy with, or intolerance to, platinum-based chemotherapy and/or anti-PD-1/PD-L1 immunotherapy,” the company said.
In December, Krazati received approval from the Food and Drug Administration as a treatment for certain adult patients with non-small cell lung cancer.
The biotechnology company said lung cancer is one of the most common cancers worldwide.
Write to Stephen Nakrosis at stephen.nakrosis@wsj.com
Read the full article here
